Drug Profile


Alternative Names: AD-5423; DSP-5423; DSP-5423P; Lonasen

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Dainippon Sumitomo Pharma; Nitto Denko; Sumitomo Dainippon Pharma
  • Class Antipsychotics; Piperazines; Piperidines
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Schizophrenia

Most Recent Events

  • 21 Feb 2017 Registered for Schizophrenia in China (PO)
  • 21 Aug 2015 Phase-III development for Schizophrenia (In adolescents) is ongoing in Japan (PO) (JapicCTI-111724, JapicCTI-111725)
  • 17 Mar 2015 Sumitomo Dainippon plans a phase III trial for Schizophrenia in Japan (NCT02335658)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top